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Available online 6 February 2016Background: Both type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are common age-associated
disorders and T2DM patients show an increased risk to suffer from AD, however, there is currently no marker
to identify who in T2DM populations will develop AD. Since glycogen synthase kinase-3β (GSK-3β) activity,
ApoE genotypes and olfactory function are involved in both T2DM and AD pathogenesis, we investigate whether
alterations of these factors can identify cognitive impairment in T2DM patients.
Methods: The cognitive ability was evaluated using Minimum Mental State Examination (MMSE) and Clinical
Dementia Rating (CDR), and the mild cognitive impairment (MCI) was diagnosed by Petersen's criteria. GSK-
3β activity in platelet, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot
blotting, the ampliﬁcation refractory mutation system (ARMS) PCR and the Connecticut Chemosensory Clinical
Research Center (CCCRC) test, respectively. The odds ratio (OR) and 95% conﬁdence intervals (95% CI) of the
biomarkers for MCI diagnosis were calculated by logistic regression. The diagnostic capability of the biomarkers
was evaluated by receiver operating characteristics (ROC) analyses.
Findings:We recruited 694 T2DMpatients from Jan. 2012 to May. 2015 in 5 hospitals (Wuhan), and 646 of them
met the inclusion criteria and were included in this study. 345 patients in 2 hospitals were assigned to the train-
ing set, and 301 patients in another 3 hospitals assigned to the validation set. Patients in each set were randomly
divided into two groups: T2DM without MCI (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). There
were no signiﬁcant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complica-
tions, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. Compared
with the T2DM-nMCI group, T2DM-MCI group showed lower MMSE score with older age, ApoE ε4 allele, higher
olfactory score and higher rGSK-3β (ratio of total GSK-3β to Ser9-phosphorylatedGSK-3β) in the training set and
the validation set. The OR values of age, ApoE ε4 gene, olfactory score and rGSK-3βwere 1.09, 2.09, 1.51, 10.08 in
the training set, and 1.06, 2.67, 1.47, 7.19 in the validation set, respectively. The diagnostic accuracy of age, ApoE
ε4 gene, olfactory score and rGSK-3βwere 0.76, 0.72, 0.66, 0.79 in the training set, and 0.70, 0.68, 0.73, 0.79 in theKeywords:
Type 2 diabetes mellitus
Mild cognitive impairment
Alzheimer's disease
Glycogen synthase kinase-3β
Olfactory score
ApoE genelzheimer's disease; GSK-3β, glycogen synthase kinase-3β; MMSE, minimum mental state examination; CDR, clinical dementia
ion refractory mutation system; CCCRC, Connecticut Chemosensory Clinical Research Center; OR, odds ratio; CI, conﬁdence in-
area under the curve; ApoE, apolipoprotein E; HbA1c, hemoglobin A1c.
azhong University of Science and Technology, Wuhan 430030, China.
.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
106 Z.-P. Xu et al. / EBioMedicine 5 (2016) 105–113validation set, respectively. These four combined biomarkers had the area under the curve (AUC) of 82% and 86%,
diagnostic accuracy of 83% and 81% in the training set and the validation set, respectively.
Interpretation: Aging, activation of peripheral circulating GSK-3β, expression of ApoE ε4 and increase of olfactory
score are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these biomarkers
can improve the diagnostic accuracy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are
the most common age-associated disorders and the prevalence of the
diseases is increasing with population aging (Biessels et al., 2008;
Exalto et al., 2012; Stumvoll et al., 2005; Umegaki, 2014). The epidemi-
ological study (Strachan et al., 2011) shows that T2DM patients show a
1.5–2.0-fold increased risk of AD. In a longitudinal cohort study lasting
up to 9 years, the risk of developing AD was 65% higher in persons
with diabetes than in non-diabetic controls (Arvanitakis et al., 2004).
A community-based controlled study suggests that frank diabetes
(35%) or glucose intolerance (46%) may be present in up to 80% of AD
patients (Janson et al., 2004). Over a maximum 11 years of follow-up,
diabetic patients experienced a higher incidence of AD than non-
diabetic subjects (0.48% vs. 0.37%) (Huang et al., 2014). Diabetes is asso-
ciated with a 50–100% increased risk of AD (Biessels et al., 2008).
The long preclinical phase of AD provides opportunity for interven-
tion (Ballard et al., 2011). Compared to healthy individuals, the patients
withmild cognitive impairment (MCI) have an increased risk to develop
AD (Petersen et al., 1999). Therefore, early diagnosis ofMCI is critical for
developing efﬁcient interventions to postpone or prevent AD. This re-
quires developing new diagnostic tools to predict dementia among the
high risk people with MCI.
Since the pathophysiological events leading to dementia precede the
clinical symptoms, biomarkers for MCI have become an area of great in-
terest for both researchers and clinicians (Tan et al., 2014). The biomarker
measurements are principally of brain amyloidosis (amyloid positron
emission tomography, cerebrospinal ﬂuid Aβ42) and neurodegeneration
(medial temporal atrophy on MR, ﬂuorodeoxyglucose positron emission
tomography, CSF tau) (Bocchetta et al., 2015). However, thesewidely val-
idated biomarkers are hampered by practical difﬁculty that severely limit
their application in large populations. Thus, ﬁnding non-invasive and
cost-effective biomarkers is of great importance for the early diagnosis.
Olfactory dysfunction is an early clinical feature in AD patients
(Devanand et al., 2010; Graves et al., 1999; Naka et al., 2010),
which can predict the incidence of MCI and its conversion into AD
(Rahayel et al., 2012). The apolipoprotein E (ApoE) ε4 allele is a
dose-dependent risk factor for AD (Farrer et al., 1997; Weisgraber,
1994), and AD patients with ApoE ε4 usually show an earlier age of
onset and a more rapid progression of the disease (Corder et al.,
1993). Olfactory impairment together with ApoE ε4 genotype can
be a marker for cognitive decline (Graves et al., 1999), although it
is also reported that the ApoE gene plays a role in olfactory function-
ing that is independent of dementia conversion within 5 years
(Olofsson et al., 2010). Glycogen synthase kinase-3β (GSK-3β) is a
serine/threonine kinase that regulates diverse cellular functions
ranging from glycogen metabolism to gene transcription and cell
survival (Grimes and Jope, 2001; Woodgett, 1990). The GSK-3β ac-
tivity is increased in AD and MCI patients, and activation of GSK-3β
causes tau hyperphosphorylation and Aβ overproduction (Hye
et al., 2005; Pei et al., 1997; Plattner et al., 2006). These studies sug-
gest that the olfactory dysfunction, GSK-3β activation and ApoE ε4
expression are predicting factors of cognitive impairments.
It is very likely that the future diagnosis and treatment of MCI will
rely on the combination of clinical and laboratory data. To our knowl-
edge, no associations with potential biomarker proﬁles or cognitive
function in T2DM patients have been published. In this study, we aimto establish diagnostic accuracy of the peripheral platelet GSK-3β activ-
ity, the ApoE gene polymorphisms and the olfactory score in directing
MCI from T2DM patients.
2. Methods
2.1. Study Design and Participants
We recruited T2DM patients from ﬁve hospitals in China between
January 2012 and May 2015, and the T2DM patients were diagnosed
by the World Health Organization (WHO) National Diabetic Group
Criteria of 2006 (Olokoba et al., 2012). The inclusion criteria were as
follows: T2DMpatients aged over 50 yearswhoare literate, able to com-
plete the neuropsychological test and volunteer to participate in this
study. The exclusion criteria include history of head trauma, brain
tumor, epilepsy, stroke, transient ischemic attack, coma, or presence of
dementia before T2DM; previous thyroid disease; drug abuse, substance
abuse, and alcohol addiction; depression, schizophrenia and other psy-
chiatric disorders. According to Petersen's MCI criteria (Petersen et al.,
1999), T2DM patients were classiﬁed into two groups: T2DM with
MCI (T2DM-MCI), whichmet criteria for subjective and objective cogni-
tive difﬁculties in the absence of signiﬁcant functional loss, and T2DM
withoutMCI (T2DM-nMCI). AD diagnosis is based on the National Insti-
tute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (McKhann et al., 1984).
All participants gave written informed consent and were treated in
accordance with the Declaration of Helsinki. The study was approved
by Tongji Medical School Ethics Committee.
2.2. Procedures
All participants underwent a complete assessment as the following:
neuropsychological evaluation, olfactory score test, platelet GSK-3β ac-
tivitymeasurement andApoE genotyping. The neuropsychological eval-
uations mainly included the Minimum Mental State Examination
(MMSE) and the Clinical Dementia Rating (CDR), which were done by
two examinerswhohad neurology training and experiencewith neuro-
physiologic techniques. TheMMSE scale, one of the best-known and the
most widely used brief screening instruments for cognitive impairment,
provides a total score ranging from 0 to 30, with lower scores indicative
of greater cognitive impairment. The CDR scale is a numeric scale used
to quantify the severity of symptoms of dementia from six areas: mem-
ory, orientation, judgment and problem solving, community affairs,
home and hobbies, and personal care. In this study, we used the
Petersen's MCI criteria as the reference standard. In addition, MMSE
and CDR scores for MCI diagnosis were 24–27 and 0.5, respectively.
The Connecticut Chemosensory Clinical Research Center (CCCRC)
test was used to measure the olfactory score, which was done blind to
the other measures by the examiners. A stock solution with 4% butanol
was diluted with distilled water as one third ratio to eight dilutions in
eight ﬂasks. The participants were exposed to the ﬂasks from low to
high concentrations of butanol along with a blank, and were asked to
identify which one smelled stronger. Incorrect choices triggered anoth-
er blank paired with the next higher concentration, whereas correct
choices led to another presentation of the same concentration in anoth-
er bottle and a blank. Four correct choices in a row led to the end of the
Fig. 1. Study proﬁle.
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scores indicated greater olfactory impairment.
For biochemical indicators, all participants were asked to mea-
sure fasting blood glucose, postprandial blood glucose, serum insu-
lin, hemoglobin A1c (HbA1c) and serum magnesium the next
morning. On receipt, serum, leukocytes and platelet samples were
separated from EDTAwhole blood by centrifugation, whichwere col-
lected and stored at−80 °C until analysis. The total GSK-3β (tGSK-
3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive
form of the kinase) in serum or platelet were measured by ELISA
(CUSABIO BIOTECH CO., Ltd., China), Western blotting or dot blot-
ting. The ratio of tGSK-3β/pS9GSK-3β was used as a measure of
GSK-3β activity. In dot blotting, the levels of tGSK-3β and pS9GSK-
3βwere normalized by the same control people (non-T2DM). In ad-
dition, the biochemical activity of GSK-3β in platelet was measured
by using enzyme activity assay kit according to the manufacturer's
guidance (Genmed, MA, USA).
For ApoE genotyping, the Gerard's method with modiﬁcations
in the multiplex ampliﬁcation refractory mutation system PCR
(ARMS) was applied (Donohoe et al., 1999; Kim et al., 2000). Geno-
mic DNA was extracted from peripheral blood leukocytes using
DNA extraction kit (Aidlab Biotechnologies Co., Ltd., China). The
primers were designed and synthesized by Invitrogen Life Tech-
nologies (Shanghai, China) for ApoE with speciﬁc Cys primers
(Cys112:5′-CGCGGACATGGAGGACGTTT-3′, and Cys158:5′-ATGCCG
ATGACCTGCAGAATT-3′), Arg primers (Arg112:5′- CGCGGACATGGATable 1
Baseline characteristics of T2DM patients in the training set and the validation set.
Characteristic The training set The validation set
T2DM-nMCI
(n = 260)
T2DM-MCI
(n = 85)
T2DM-nMCI
(n = 201)
T2DM-MCI
(n = 100)
Age (years) 60.31 ± 6.34 65.34 ± 8.37⁎ 63.24 ± 8.00 67.91 ± 8.68⁎
Male (%) 42.31% 37.65% 46.77% 35.00%
T2DM years 7.29 ± 5.27 8.49 ± 6.86 8.45 ± 6.89 8.80 ± 7.85
Hypertension 45.38% 37.65% 53.23% 62.00%
Hyperlipidemia 6.54% 4.71% 8.96% 11.00%
Coronary disease 8.85% 3.53% 8.46% 15.00%
Complication 64.23% 58.83% 47.26% 42.00%
Insulin treatment 47.69% 44.71% 41.79% 36.00%
MMSE 29.05 ± 0.85 26.00 ± 1.13⁎ 29.10 ± 0.80 24.94 ± 2.94⁎
Data are mean ± SD or n (%). T2DM = type 2 diabetes mellitus. MCI = mild cognitive
impairment. T2DM-nMCI = T2DM without MCI group. T2DM-MCI = T2DM with MCI
group. MMSE = the MinimumMental State Examination.
⁎ P b 0.05 versus the T2DM-nMCI group.GGACGTTC-3′, and Arg158:5′-ATGCCGATGACCTGCAGAATC-3′), and
a common reverse primer (5′-GTTCAGTGATTGTCGCTGGGCA-3′).
The PCR protocol was performed with 12.5 μl Taq MasterMix, 50 ng
genomic DNA, 0.4 μM Cys112/Arg112 primers or 0.8 μM Cys158/
Arg158 primers, 0.8 μM common reverse primers, and 2 μl DMSO in
a total of 25 μl reaction. PCR was initiated with denaturation at
94 °C for 2 min, ampliﬁcation by 36 cycles of 94 °C for 45 s, 64 °C
for 45 s and 72 °C for 45 s, and a ﬁnal extension at 72 °C for 5 min.
Amplicons were resolved by 1.8% agarose gel electrophoresis and
stained with GoldView Dye.
2.3. Statistical Analysis
Data analysiswas performed by separate raterswhoare experienced
university teachers in statistics using SPSS 19.0 window software (sta-
tistical package for the Social sciences, SPSS Inc). The continuous vari-
ables and the categorical variables were presented respectively as
mean± SD and frequency (%). Chi square and t-test were used to com-
pare case versus controls for categorical variables and continuous vari-
ables, respectively. All P values reported were considered statistically
signiﬁcant if P b 0.05.
To test whether the individual biomarker was independently asso-
ciated with MCI diagnosis in T2DM patients, we constructed logistic re-
gressionmodels. We calculated the odds ratio (OR) and 95% conﬁdence
intervals (95% CI) for MCI of these biomarkers. A cut-off value of single
biomarker reﬂecting the best combination of sensitivity and speciﬁcityTable 2
Potential markers of T2DM patients in the training set and the validation set.
Characteristic The training set The validation set
T2DM-nMCI
(n = 260)
T2DM-MCI
(n = 85)
T2DM-nMCI
(n = 201)
T2DM-MCI
(n = 100)
Olfactory 6.31 ± 1.33 7.37 ± 1.91⁎ 6.76 ± 1.48 8.02 ± 1.82⁎
HbA1c 8.19 ± 2.12 8.27 ± 2.09 7.82 ± 1.81 8.20 ± 1.89
ApoE ε2 11.92% 11.76% 23.88% 21.00%
ApoE ε3 96.92% 94.12% 93.03% 87.00%
ApoE ε4 13.08% 27.06%⁎ 10.45% 25.00%⁎
tGSK3β 1.34 ± 1.93 1.92 ± 3.16 1.85 ± 3.62 2.74 ± 3.97
pS9GSK3β 2.13 ± 4.00 2.94 ± 6.53 3.02 ± 3.92 2.64 ± 4.05
rGSK3β 0.76 ± 0.28 1.19 ± 0.67⁎ 0.70 ± 0.46 1.66 ± 1.04⁎
Data are mean ± SD or n (%). T2DM = type 2 diabetes mellitus. MCI = mild cognitive
impairment. T2DM-nMCI = T2DM without MCI group. T2DM-MCI = T2DM with MCI
group. HbA1c = hemoglobin A1c. ApoE = Apo lipoprotein E. GSK-3β = glycogen
synthase kinase-3β. GSK-3β ratio = total GSK-3β/Ser9-GSK-3β.
⁎ P b 0.05 versus the T2DM-nMCI group.
Fig. 2. Six ApoE genotypes detected in this study. We detected six ApoE genotypes: ε2ε2, ε3ε3, ε4ε4, ε2ε3, ε2ε4, and ε3ε4 in T2DM patients.
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curacy were calculated. Receiver operating characteristic curves (ROC)
were plotted to assess the diagnostic accuracy of GSK-3β and the com-
bined biomarkers.
3. Results
We screened 694 T2DM patients between Jan. 2012 and May 2015,
and 646 of them met the inclusion criteria, thus were enrolled for the
study (Fig. 1). Based on the recruiting time and the hospitals, 345
patients in 2 hospitals were assigned to the training set, and 301 of them
in 3 hospitals were assigned to the validation set. According to Petersen's
MCI criteria, the T2DM patients were divided into 85 T2DM with MCIFig. 3. The differences of ApoE between T2DM-nMCI group and T2DM-MCI group in the training
T2DM-nMCI group, and the ε3ε3 genotype in T2DM-MCI group was lower than that in T2DM-(T2DM-MCI) and 260 T2DM without MCI (T2DM-nMCI) in the training
set, and 201 T2DM-nMCI and 100 T2DM-MCI in the validation set.
3.1. Demographics and Clinical Characteristics of the Participants
Table 1 shows the demographic and clinical data of all the partici-
pants in the training set and the validation set. T2DM-MCI group had
older age (65.34 ± 8.37 vs 60.31 ± 6.34 and 67.91 ± 8.68 vs 63.24 ±
8.00) and lower MMSE score (26.00 ± 1.13 vs 29.05 ± 0.85 and
24.94 ± 2.94 vs 29.10 ± 0.80) than T2DM-nMCI group in the training
set and the validation set, respectively. There were no signiﬁcant differ-
ences for sex, T2DM years, hypertension, hyperlipidemia, coronary dis-
ease, complications and insulin treatment. T2DM-MCI participants hadset and the validation set. The ε3ε4 genotype in T2DM-MCI groupwas higher than that in
nMCI. *P b 0.05 versus the T2DM-nMCI group.
Fig. 4. The difference of GSK-3β expressions in serumbetween T2DM-nMCI group (n=7)
and T2DM-MCI group (n= 12). The expressions of GSK-3β in serum of T2DM-MCI group
were higher than those in T2DM-nMCI group *P b 0.05 versus the T2DM-nMCI group.
Fig. 5. The differences of platelet GSK-3β activity between control group (n = 6), T2DM-
nMCI group (n= 34) and T2DM-MCI group (n= 33). T2DM-MCI group had higher GSK-
3β activity than T2DM-nMCI group, and T2DM-nMCI group had higher GSK-3β activity
than control group in the platelet. *P b 0.05, **P b 0.01 versus the NC group or T2DM-
nMCI group.
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was negatively correlated with the ages in T2DM patients (P b 0.001,
Fig. S1).3.2. Comparison of Olfactory Score and ApoE Genotypes between
T2DM-MCI and T2DM-nMCI Patients
We tested all 646 participants with olfactory score, HbA1c level and
ApoE genotypes. The olfactory score was higher in T2DM-MCI group
than the T2DM-nMCI group (Table 2). A strong and signiﬁcant negative
correlation was detected between olfactory score and MMSE score in
T2DMpatients (P b 0.001, Fig. S2). By ARMS-PCR, six ApoE genotypes in-
cluding ε2ε2, ε3ε3, ε4ε4, ε2ε3, ε2ε4, and ε3ε4were detectable in T2DM
patients (Fig. 2). Quantitative data demonstrated that the frequency of
ε3ε4 genotype was higher while ε3ε3 was lower in T2DM-MCI groupFig. 6. The comparison of GSK-3β expressions in the platelets of different participants byWeste
Dot blot.than T2DM-nMCI group, and no differences of ε2ε2, ε4ε4, ε2ε3 and
ε2ε4 were detected between the two groups (Fig. 3). Further analyses
showed that percentage of ε4 allele was higher in T2DM-MCI group
than the T2DM-nMCI group in both the training set and the validation
set (Table 2). Moreover, the ApoE ε4 (+) group had lowerMMSE scores
than ApoE ε4 (−) group in T2DM patients (P b 0.01, Fig. S3).
3.3. Comparison of Platelet GSK-3β Activity Between T2DM-MCI and
T2DM-nMCI Patients
By ELISA, we found that serum level of GSK-3β proteinwas higher in
T2DM-MCI group (n = 12) than T2DM-nMCI group (n = 7, Fig. 4). By
using the enzyme activity assay kit, we conﬁrmed that T2DM-MCI
group (n = 33) had higher platelet GSK-3β activity than T2DM-nMCI
group (n = 34), and the T2DM-nMCI had higher GSK-3β activity than
control group (n = 6, Fig. 5). To further verify whether the level of
GSK-3β in platelet can be used as a clinical diagnostic biomarker to
identify MCI in T2DM patients, we analyzed the total and pS9GSK-3β
by Western blotting and dot blotting. We ﬁrst veriﬁed that results of
dot blots were consistent with those of Western blots (Fig. 6). As the
procedure of dot blotting ismuch simpler than that ofWestern blotting,
we used dot blotting for the analyses of tGSK-3β and pS9GSK-3β pro-
teins in all 646 participants. The ratio of tGSK-3β/pS9GSK-3β (rGSK-
3β) was used to represent platelet GSK-3β activity, and higher ratios
indicated higher GSK-3β activity. We found that levels of pS9GSK-3β
(the inactive form of the kinase) and tGSK-3β were not signiﬁcantly
changed, while the level of rGSK-3β was signiﬁcantly increased in
T2DM-MCI patients compared to T2DM-nMCI patients (Fig. 7,
Table 2). In addition, T2DM-AD group had higher rGSK-3β than
T2DM-MCI group, and T2DM-MCI group had higher rGSK-3β than
T2DM-nMCI group in the platelets (Fig. 8). A negative correlation be-
tween platelet rGSK-3β and MMSE score was seen in T2DM patients
(P b 0.001, Fig. S4).
3.4. Potential Diagnostic Biomarkers for Identifying MCI in T2DM Patients
We used logistic regression models to calculate the odds ratio (OR)
and 95% conﬁdence intervals (95% CI) for MCI of all biomarkers. We
found that age, ApoE ε4 gene, olfactory score and platelet GSK-3β activ-
ity were strongly associatedwithMCI in T2DMpatients (Table 3). In the
training set, the OR values (95% CI) of age, ApoE ε4 gene, olfactory score
and rGSK-3βwere 1.09 (1.05–1.14), 2.09 (1.00–4.35), 1.51 (1.24–1.85)
and 10.80 (4.49–26.00), respectively. In the validation set, theOR values
(95% CI) of age, ApoE ε4 gene, olfactory score and rGSK-3β were 1.06
(1.02–1.10), 2.67 (1.21–5.90), 1.47 (1.21–1.79) and 7.19 (3.92–13.16),
respectively (Table 3). These data suggest that increases of age, ApoE
ε4 gene, olfactory score and platelet rGSK-3β may be diagnostic for
MCI in T2DM patients.
3.5. Diagnostic Efﬁcacy of Single Biomarker
We applied ROC models to calculate the area under the curve
(AUC), the accuracy, the speciﬁcity and sensitivity of singlern blot and Dot blot. The results of Western blot analysis were in accordance with those of
Fig. 7. Thedifferences of plateletGSK-3β activity between T2DM-nMCI group and T2DM-MCI group byWestern blot andDot blot. (A) The expressions of total GSK-3β and p-GSK-3β (ser9)
in the platelet byWestern blot; (B) the expressions of total GSK-3β and p-GSK-3β (ser9) in the platelet by Dot blot; (C) quantitative analysis ofWestern blot; (D) Quantitative analysis of
Dot blot. *P b 0.05 versus T2DM-nMCI group.
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lowing formulas for the calculations: % sensitivity = [true-positive /
(true-positive + false-negative)] × 100; % speciﬁcity = [true-nega-
tive / (true-negative + false-positive)] × 100. Age had a maximal
AUC of 68.0% and an accuracy of 76.0% in the training set, and a max-
imal AUC of 65.0% and an accuracy of 70.0% in the validation set
(Table 4). The diagnostic value of olfactory score for MCI revealed a
AUC of 72.0% and an accuracy of 66.0% against controls. In ApoE
gene polymorphisms, ε4 allele showed accuracy of 72.0% and 68.0%
in the training set and the validation set, respectively. The rGSK-3β
for MCI diagnosis resulted in an AUC of 69.0% and an accuracy of
79.0% in the training set, and an AUC of 81.0% and an accuracy of
79.0% in the validation set. Therefore, the remaining analyses fo-
cused on age, platelet rGSK-3β, ApoE ε4, olfactory score and the
combinations.Fig. 8. The differences of platelet rGSK-3β between T2DM-AD group (n = 15), T2DM-
nMCI group (n = 15) and T2DM-MCI group (n = 15). T2DM-AD group had higher
rGSK-3β than T2DM-MCI group, and T2DM-MCI group had higher rGSK-3β than T2DM-
nMCI group in the platelet.3.6. Diagnostic Capability of the Combined Biomarkers
The diagnostic capability of ApoE ε4 and olfactory score were com-
bined, generating ROC curves with AUC of 72.0% and 73.0%, accuracy
of 78.0% and 73.0% in the training set and the validation set, respectively
(Table 5). By combining rGSK-3β and ApoE ε4, we generated ROC
curves with AUC of 77.0% and 80.0%, accuracy of 72.0% and 83.0% in
the training set and the validation set, respectively. Using only rGSK-
3β and olfactory score from the biomarker proﬁle, it yielded AUC of
79.0% and 84.0%, accuracy of 77.0% and 80.0% in the training set and
the validation set, respectively. The addition of rGSK3β, olfactory score
and ApoE ε4 generated ROC curves with AUC of 79.0% and 85.0%, accu-
racy of 74.0% and 80.0% in the training set and the validation set, respec-
tively (Table 5).
By combining age, platelet rGSK-3β, ApoE ε4 and olfactory score, we
generated a ROC curve with an AUC of 82.0% (95% CI 0.76–0.87) and an
accuracy of 83.0% in the training set (Model 1) (Table 5, Fig. 9). In the
validation set (Model 2), an increased AUC of 86.0% and a decreasedTable 3
Logistic regression models for MCI in T2DM patients.
Variable B S.E. Wald Sig. Exp(B) 95% CI
Lower Upper
The training set
Age 0.09 0.02 17.31 b0.001 1.09 1.05 1.14
ApoE ε4 0.74 0.37 3.87 0.049 2.09 1.00 4.35
Olfactory 0.41 0.10 16.14 b0.001 1.51 1.24 1.85
rGSK-3β 2.38 0.45 28.19 b0.001 10.80 4.49 26.00
The validation set
Age 0.06 0.02 10.02 0.002 1.06 1.02 1.10
ApoE ε4 0.98 0.40 5.93 0.015 2.67 1.21 5.90
Olfactory 0.39 0.10 15.28 b0.001 1.47 1.21 1.79
rGSK-3β 1.97 0.31 40.82 b0.001 7.19 3.92 13.16
B= the estimated logit coefﬁcient. S.E. = the standard error of the coefﬁcient. Wald= B/
S.E. Sig.= the signiﬁcance level of the coefﬁcient. Exp(B)= the odds ratio of the individual
coefﬁcient. CI = conﬁdence interval. ApoE= Apo lipoprotein E. GSK-3β= glycogen syn-
thase kinase-3β. GSK-3β ratio = total GSK-3β/Ser9-GSK-3β.
Table 4
Diagnostic efﬁcacy of single biomarker in the training set and the validation set.
Variables Cutoff Speciﬁcity Sensitivity AUC (95% CI) Accuracy
The training set
Age 65.50 0.85 0.49 0.68 (0.61,0.75) 0.76
HbA1c 7.15 0.62 0.42 0.49 (0.42,0.56) 0.57
Olfactory 6.75 0.65 0.71 0.72 (0.66,0.79) 0.66
ApoE ε2 – 0.88 0.12 – 0.69
ApoE ε3 – 0.03 0.94 – 0.26
ApoE ε4 – 0.87 0.27 – 0.72
tGSK3β 1.03 0.73 0.39 0.50 (0.42,0.58) 0.64
pS9GSK3β 0.40 0.89 0.33 0.59 (0.52,0.67) 0.75
rGSK3β 1.05 0.90 0.48 0.69 (0.62,0.76) 0.79
The validation set
Age 68.50 0.80 0.49 0.65 (0.59,0.72) 0.70
HbA1c 7.05 0.43 0.74 0.57 (0.51,0.64) 0.53
Olfactory 7.75 0.77 0.64 0.72 (0.66,0.79) 0.73
ApoE ε2 – 0.76 0.21 – 0.58
ApoE ε3 – 0.07 0.87 – 0.34
ApoE ε4 – 0.90 0.25 – 0.68
tGSK3β 1.29 0.69 0.61 0.65 (0.59,0.72) 0.66
pS9GSK3β 0.49 0.83 0.36 0.59 (0.52,0.66) 0.67
rGSK3β 1.29 0.91 0.55 0.81 (0.76,0.86) 0.79
ROC = receiver operating characteristics. AUC = the area under the curve. CI =
conﬁdence interval. GSK3β = glycogen synthase kinase-3β, tGSK3β = total GSK3β,
pS9GSK3β= serine-9 phosphorylated pS9GSK3β, rGSK3β= ratio of tGSK3β/pS9GSK3β.
111Z.-P. Xu et al. / EBioMedicine 5 (2016) 105–113accuracy of 81.0% were observed but the difference was not statistically
signiﬁcant from Model 1 (Table 5, Fig. 9).
4. Discussion
Both AD and T2DM are age-associated disorders that affect millions
of people around theworld. The incidence of AD increases to 14.2% in di-
abetic patients, and over 80% of AD patients have T2DM or show abnor-
mal blood glucose levels. Therefore, searching for biomarkers that can
diagnose or predict conversion of T2DM into AD makes it possible to
start an early intervention to prevent an outbreak of AD. In the present
study, we investigated what could be the biomarkers for the cognitive
impairments in T2DM patients, and validated the diagnostic accuracy
of these biomarkers. According to Petersen's MCI criteria, we dividedTable 5
Diagnostic efﬁcacy of the combined biomarkers.
Variables Speciﬁcity
The training set
ApoE ε4 + olfactory 0.85
ApoE ε4 + rGSK3β 0.83
ApoE ε4 + age 0.76
rGSK3β+ age 0.72
Olfactory + age 0.76
rGSK3β+ olfactory 0.78
ApoE ε4 + olfactory + rGSK3β 0.73
ApoE ε4 + olfactory + age 0.71
ApoE ε4 + rGSK3β+ age 0.78
Olfactory + rGSK3β+ age 0.80
rGSK3β+ olfactory + ApoE ε4 + age 0.91
The validation set
ApoE ε4 + olfactory 0.80
ApoE ε4 + rGSK3β 0.88
ApoE ε4 + age 0.74
rGSK3β+ age 0.86
Olfactory + age 0.75
rGSK3β+ olfactory 0.90
ApoE ε4 + olfactory + rGSK3β 0.86
ApoE ε4 + olfactory + age 0.69
ApoE ε4 + rGSK3β+ age 0.79
Olfactory + rGSK3β+ age 0.87
rGSK3β+ olfactory + ApoE ε4 + age 0.86
AUC = the area under the curve. CI = conﬁdence interval.T2DM patients into two groups, i. e., T2DM-MCI and T2MD-nMCI. As
predicted, age is an strong factor for cognitive decline in T2DM patients.
Furthermore, we ﬁrst demonstrated that age, peripheral circulating
GSK-3β activation, ApoE ε4 expression and olfactory score are diagnos-
tic for the mild cognitive impairment in T2DM patients, and combina-
tion of these biomarkers can improve the diagnostic accuracy.
Firstly, we ﬁnd that activation of GSK-3β in peripheral circulating
platelet is diagnostic of cognitive impairment in T2DM patients. Accu-
mulating laboratory evidence suggest that GSK-3β activation is in-
volved in both T2DM and AD, such as disturbed glycogen metabolism
(Rayasam et al., 2009), tau hyperphosphorylation (Martin et al.,
2013), Aβ production (Phiel et al., 2003), and neurodegeneration
(Hooper et al., 2008). Clinical studies also show that level of GSK-3β
mRNA and protein in leucocytes is increased (Hye et al., 2005; Sheng
et al., 2012), and theGSK-3β gene variants are associatedwith cognitive
function in ADpatients (Kettunen et al., 2015). However, it is not report-
edwhether GSK-3β activity is different in human T2DMpatientswith or
without cognitive impairment. In the present study, we found that the
GSK-3β activitywasmuch higher in T2DM-MCI patients than the cogni-
tively healthy T2DM patients, indicating that GSK-3β activation could
be an indicator of cognitive impairment in T2DM patients. This ﬁnding
is of great signiﬁcance because it provides a feasible tool to screen
among the rapidly increasing T2DM populations who may develop
into AD, by which we can also establish efﬁcient strategies to arrest
the conversion of T2DM into AD.
Secondly, we ﬁnd that expression of ApoE ε4 gene is strongly associ-
ated with the cognitive impairment in T2DM patients. ApoE gene has
threemajor alleles (ɛ2, ɛ3 and ɛ4) based on the amino-acid substitutions
(Arg or Cys) at 112 and 158 of the protein (Sutton et al., 2015), in which
the ApoE ɛ4 allele has a reduced ability to repair neuronal damage and a
decreased antioxidant activity compared with the ɛ2 and ɛ3 (Ma et al.,
1994). Growing genetic evidence suggests that ApoE ɛ4 allele is the
major genetic risk factor for AD (Bertram et al., 2010) and is associated
with an increased risk of MCI conversion into AD (Devanand et al.,
2005). ~70% of AD patients have one or two copies of ApoE ɛ4. The pres-
ence of ApoE ɛ4 allele confers greater amyloid burden (Fleisher et al.,
2011), changes of amyloid and tau in cerebrospinal ﬂuids (Vemuri
et al., 2010), higher degree of neurodegeneration (Caroli et al., 2010),
and alterations in brain function and glucose metabolism (LangbaumSensitivity AUC (95% CI) Accuracy
0.54 0.72 (0.65,0.79) 0.78
0.58 0.72 (0.65,0.79) 0.77
0.65 0.71 (0.64,0.78) 0.73
0.69 0.77 (0.71,0.83) 0.71
0.73 0.78 (0.72,0.83) 0.75
0.73 0.79 (0.73,0.85) 0.77
0.74 0.79 (0.73,0.85) 0.74
0.74 0.77 (0.72,0.83) 0.72
0.66 0.78 (0.72,0.84) 0.75
0.72 0.82 (0.77,0.87) 0.78
0.58 0.82 (0.76,0.87) 0.83
0.59 0.73 (0.67,0.79) 0.73
0.63 0.83 (0.78,0.88) 0.80
0.64 0.69 (0.62,0.75) 0.70
0.70 0.83 (0.78,0.88) 0.81
0.73 0.77 (0.71,0.82) 0.74
0.60 0.84 (0.79,0.88) 0.80
0.69 0.85 (0.80,0.89) 0.80
0.76 0.78 (0.72,0.83) 0.71
0.78 0.84 (0.79,0.89) 0.79
0.67 0.86 (0.81,0.90) 0.80
0.71 0.86 (0.82,0.91) 0.81
Fig. 9. ROC (receiver operating curves) show diagnostic efﬁcacy of the combined biomarkers (age, ApoE ε4 gene, olfactory threshold and GSK-3β ratio) in the training set and the
conﬁrmation in the validation set.
112 Z.-P. Xu et al. / EBioMedicine 5 (2016) 105–113et al., 2009). The T2DM patients carrying ApoE ɛ4 allele had a higher
number of hippocampal neuritic plaques and neuroﬁbrillary tangles in
the cortex and hippocampus, and they had a higher risk of cerebral am-
yloid angiopathy (Peila et al., 2002). In the current study,we are theﬁrst
to show that the expression of ApoE ɛ4 allele is strongly associated with
the cognitive impairment in T2DMpatients, which provides a viable ge-
netic factor for screening the high AD risk individuals in T2DM patients.
Thirdly,weﬁnd that reduction of olfactory score is indicative for cog-
nitive impairment in T2DMpatients. Olfactory dysfunction is a common
and early symptom of many neurodegenerative diseases, particularly of
AD and MCI (Attems et al., 2014; Lehrner et al., 2009; Christen-Zaech
et al., 2003). ~86% of normal elderly participants present with
Alzheimer-type neuroﬁbrillary tangles in the olfactory bulbs, and one
third of them also have amyloid deposition (Kovacs, 2004). Studies
show that the identiﬁcation of olfactory impairment has clinical utility
as an early diagnostic biomarker for MCI and AD (Devanand et al.,
2000; Djordjevic et al., 2008; Vyhnalek et al., 2015). In the present
study, we ﬁnd a strong association of smell identiﬁcation deﬁcit with
cognitive impairment in T2DM patients, which provides an applicable
clinical tool in screening the potential AD conversion in T2DM patients.
We also ﬁnd that combination of ApoE ε4 gene, olfactory score and the
ratio of tGSK-3β/pS9GSK-3β can improve the AUC and accuracy of MCI
diagnosis in T2DM patients.
Additionally, we developed a simple protocol (dot blot) for mea-
surement of total and pS9GSK-3β in human platelets. As this method
is simple handling and has good reproducibility, we believe that the
method may be suitable for application in clinical laboratories. Platelets
and neurons have several homeostatic functions in common, such as ac-
cumulation and release of neurotransmitters, expression of membrane-
bound compounds, and responsiveness to variations in calcium concen-
tration (El Haouari and Rosado, 2009).
The major limitation of the current study is the follow-up investiga-
tion to the same participants, although we have designed training set
and validation set to redeem this weakness. Further multi-center and
longitudinal studies will conﬁrm how informative these biomarkers in
predicting the conversion of T2DM into AD.
In conclusion, we show in the present study that the alterations and
the combined application of age, ApoE ε4 gene, olfactory score and
tGSK-3β/pS9GSK-3β ratio are diagnostic for mild cognitive deﬁcits in
T2DM patients, which shed light on developing preventive strategies
to arrest conversion of T2DM into AD.
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